<html><head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
</head><body>
<span style="position:absolute; border: gray 1px solid; left:0px; top:50px; width:612px; height:792px;"></span>
<div style="position:absolute; top:50px;"><a name="1">Page 1</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:80px; width:27px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Research
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:109px; width:345px; height:108px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:8px">Original Investigation
<br></span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:16px">Overdiagnosis of </span><span style="font-family: GNJKIK+GuardianSans-MediumIt; font-size:16px">Clostridium difficile </span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:16px">Infection
<br>in the Molecular Test Era
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Christopher R. Polage, MD, MAS; Clare E. Gyorke, BS; Michael A. Kennedy, BS; Jhansi L. Leslie, BS;
<br>David L. Chin, PhD; Susan Wang, BS; Hien H. Nguyen, MD, MAS; Bin Huang, MD, PhD; Yi-Wei Tang, MD, PhD;
<br>Lenora W. Lee, MD; Kyoungmi Kim, PhD; Sandra Taylor, PhD; Patrick S. Romano, MD, MPH;
<br>Edward A. Panacek, MD, MPH; Parker B. Goodell, BS, MPH; Jay V. Solnick, MD, PhD; Stuart H. Cohen, MD
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:79px; top:243px; width:317px; height:56px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">IMPORTANCE </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">is a major cause of health care–associated infection, but
<br>disagreement between diagnostic tests is an ongoing barrier to clinical decision making and
<br>public health reporting. Molecular tests are increasingly used to diagnose </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">infection
<br>(CDI), but many molecular test-positive patients lack toxins that historically defined disease,
<br>making it unclear if they need treatment.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:79px; top:312px; width:322px; height:22px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">OBJECTIVE </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">To determine the natural history and need for treatment of patients who are toxin
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">immunoassay negative and polymerase chain reaction (PCR) positive (Tox−/PCR+) for CDI.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:79px; top:346px; width:322px; height:45px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">DESIGN, SETTING, AND PARTICIPANTS </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">Prospective observational cohort study at a single
<br>academic medical center among 1416 hospitalized adults tested for </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">toxins 72 hours
<br>or longer after admission between December 1, 2010, and October 20, 2012. The analysis was
<br>conducted in stages with revisions from April 27, 2013, to January 13, 2015.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:79px; top:403px; width:321px; height:68px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">MAIN OUTCOMES AND MEASURES </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">Patients undergoing </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">testing were grouped by US
<br>Food and Drug Administration–approved toxin and PCR tests as Tox+/PCR+, Tox−/PCR+, or
<br>Tox−/PCR−. Toxin results were reported clinically. Polymerase chain reaction results were not
<br>reported. The main study outcomes were duration of diarrhea during up to 14 days of
<br>treatment, rate of CDI-related complications (ie, colectomy, megacolon, or intensive care unit
<br>care) and CDI-related death within 30 days.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:79px; top:484px; width:322px; height:125px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">RESULTS </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">Twenty-one percent (293 of 1416) of hospitalized adults tested for </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">were
<br>positive by PCR, but 44.7% (131 of 293) had toxins detected by the clinical toxin test. At
<br>baseline, Tox−/PCR+ patients had lower </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">bacterial load and less antibiotic exposure,
<br>fecal inflammation, and diarrhea than Tox+/PCR+ patients (</span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">&lt; .001 for all). The median
<br>duration of diarrhea was shorter in Tox−/PCR+ patients (2 days; interquartile range, 1-4 days)
<br>than in Tox+/PCR+ patients (3 days; interquartile range, 1-6 days) (</span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">= .003) and was similar
<br>to that in Tox−/PCR− patients (2 days; interquartile range, 1-3 days), despite minimal empirical
<br>treatment of Tox−/PCR+ patients. No CDI-related complications occurred in Tox−/PCR+
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">patients vs 10 complications in Tox+/PCR+ patients (0% vs 7.6%, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">&lt; .001). One Tox−/PCR+
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">patient had recurrent CDI as a contributing factor to death within 30 days vs 11 CDI-related
<br>deaths in Tox+/PCR+ patients (0.6% vs 8.4%, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">= .001).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:79px; top:621px; width:316px; height:79px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">CONCLUSIONS AND RELEVANCE </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">Among hospitalized adults with suspected CDI, virtually all
<br>CDI-related complications and deaths occurred in patients with positive toxin immunoassay
<br>test results. Patients with a positive molecular test result and a negative toxin immunoassay
<br>test result had outcomes that were comparable to patients without </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:7px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:7px">by either
<br>method. Exclusive reliance on molecular tests for CDI diagnosis without tests for toxins or
<br>host response is likely to result in overdiagnosis, overtreatment, and increased health care
<br>costs.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:79px; top:757px; width:227px; height:17px;"><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">JAMA Intern Med</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2015;175(11):1792-1801. doi:10.1001/jamainternmed.2015.4114
<br>Published online September 8, 2015.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:40px; top:790px; width:14px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1792
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:808px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:439px; top:231px; width:65px; height:19px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Invited Commentary
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">page 1801
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:439px; top:257px; width:81px; height:19px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Supplemental content </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">at
<br>jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:439px; top:283px; width:82px; height:29px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">CME Quiz </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">at
<br>jamanetworkcme.com and
<br></span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">CME Questions </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">page 1880
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:426px; top:673px; width:106px; height:101px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Author Affiliations: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Author
<br>affiliations are listed at the end of this
<br>article.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Corresponding Author: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Christopher
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">R. Polage, MD, MAS, Department of
<br>Pathology and Laboratory Medicine,
<br>University of California Davis School
<br>of Medicine, Specialty Testing Center
<br>Bldg, 3740 Business Dr, Sacramento,
<br>CA 95820 (christopher.polage
<br>@ucdmc.ucdavis.edu).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:416px; top:790px; width:35px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:458px; top:790px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><span style="position:absolute; border: black 1px solid; left:67px; top:234px; width:347px; height:539px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:62px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:721px; width:347px; height:122px;"></span>
<span style="position:absolute; border: black 1px solid; left:79px; top:307px; width:323px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:79px; top:341px; width:323px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:79px; top:398px; width:323px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:79px; top:479px; width:323px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:79px; top:616px; width:323px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:426px; top:234px; width:9px; height:9px;"></span>
<span style="position:absolute; border: black 1px solid; left:428px; top:238px; width:7px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:428px; top:235px; width:2px; height:5px;"></span>
<span style="position:absolute; border: black 1px solid; left:426px; top:260px; width:9px; height:9px;"></span>
<span style="position:absolute; border: black 1px solid; left:431px; top:261px; width:0px; height:6px;"></span>
<span style="position:absolute; border: black 1px solid; left:428px; top:264px; width:6px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:426px; top:285px; width:9px; height:9px;"></span>
<span style="position:absolute; border: black 1px solid; left:431px; top:287px; width:0px; height:6px;"></span>
<span style="position:absolute; border: black 1px solid; left:428px; top:290px; width:6px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:832px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:832px; width:378px; height:8px;"></span>
<span style="font-family: Times-Bold; font-size:6px">Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:892px; width:612px; height:792px;"></span>
<div style="position:absolute; top:892px;"><a name="2">Page 2</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:922px; width:227px; height:695px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:37px">C </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">lostridium difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">is one of the most common causes
<br>of health care–assoc iated infection in US hospitals,
<br>a f fec t ing a lmos t 1% o f hosp ita l ized pat ients each
<br>year. </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">1-3 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">S ince 2000, the inc idence of </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C d iff ic i le </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">infec t ion
<br>(CDI) has increased more than 200% while the rates of other
<br>hea l th c a re–assoc iated in fec t ions have dec reased . </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">1 , 2 ,4 -6
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">More than 300 000 hosp ita l izat ions invo lve a CD I each
<br>year, at an annual cost of $1.0 to $4.9 billion to the US health
<br>care system.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">2,7
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Initial increases in the rate of CDI were attributed to the
<br>emergence of a novel, hypervirulent strain during a period
<br>when at least 95% of hospitals used toxin immunoassays for
<br>diagnosis (2000-2008).</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">3,5,8-10 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">More recent increases have
<br>been linked to greater </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff icile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">detection after the intro-
<br>duction of molecular tests, which are more sensitive and
<br>detect microbial DNA instead of toxin.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">10-15 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Individual hospi-
<br>tals have reported a 50% to 100% increase in the rate of CDI
<br>after sw itching from toxin tests to molecular tests.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">11 ,12 ,14
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Similar increases have been observed in the rate of publicly
<br>repo r ted CD I a s repo r t ing f a c i l i t ie s adop ted mo le c u la r
<br>tests.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">15
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">For decades, toxin tests were favored over culture for
<br>diagnosis of CDI because toxins mediate disease and toxin
<br>detection was faster and provided evidence of toxin produc-
<br>t ion in v ivo that typ ic a l ly corre lated better w ith c l in ic a l
<br>disease.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">3,10,16-18 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Molecular tests such as polymerase chain
<br>reaction (PCR) target toxin genes but are similar to culture
<br>in detecting </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff icile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">bacteria regardless of toxin produc-
<br>tion, making it unclear whether positive PCR results reflect
<br>clinical disease.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">3,10,19-21 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">The uncertain clinical significance
<br>of positive PCR results is problematic in inpatient health
<br>care facilities, where </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">colonization is 5 to 10 times
<br>m o r e c omm o n t h a n CD I a n d n o n i n f e c t i o u s c a u s e s o f
<br>diarrhea are also common.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">22-26 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Nonetheless, concern that
<br>p a t i e n t s w i t h C D I w e r e b e i n g m i s s e d b y t o x i n t e s t s
<br>prompted many laboratories to sw itch to molecular tests
<br>in 2009 , when they be c ame ava i lab le . </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">1 0 , 1 9 , 2 7 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">A s o f the
<br>first quarter of 2014, a total of 44% of acute care hospitals
<br>part ic ipat ing in the Nat iona l Hea lthc are Safety Network
<br>(NHSN) reported using molecular tests alone or in combina-
<br>tion w ith other tests for diagnosis of CDI (NHSN, written
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">communication, September 15, 2014). Therefore, there is
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">an urgent need to determine whether patients with negative
<br>toxin test results and positive molecular test results have
<br>C D I o r a r e s i m p l y c o l o n i z e d w i t h a n o t h e r c a u s e o f
<br>symptoms.
<br>To address this need, we prospectively tested hospital-
<br>ized adults with suspected CDI at the University of Califor-
<br>nia Davis Medical Center with molecular tests while main-
<br>taining our existing toxin test for clinical diagnosis. We then
<br>collected clinical outcome and treatment data to enable us
<br>to ask 3 related questions. First, what is the natural history
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">of PCR-positive patients with negative toxin immunoassay
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">results? Second, how do outcomes in these patients com-
<br>pare with outcomes in patients with positive toxin and PCR
<br>results or completely negative </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">test results? Third,
<br>do PCR-positive patients with negative toxin results require
<br>treatment for CDI?
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:448px; top:922px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Original Investigation Research
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:963px; width:40px; height:14px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:9px">Methods
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:987px; width:227px; height:160px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Study Design and Population
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Hospitalized adults with a diarrheal stool sample submitted
<br>for </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">testing 72 hours or longer after admission to the
<br>University of California Davis Medical Center between Decem-
<br>ber 1, 2010, and October 20, 2012, were included in the study.
<br>Only the first sample was analyzed for each patient. Samples
<br>received after discharge were excluded. Patients with </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diffi-
<br>cile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">detected by culture and no other test were excluded from
<br>the study. The study protocol was approved by the University
<br>of California Davis Institutional Review Board. Informed con-
<br>sent was waived for the initial screening and symptom veri-
<br>fication and overall outcome and safety analysis. A subset of
<br>patients had written informed consent obtained for addi-
<br>tional in-person follow-up.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:1159px; width:227px; height:343px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Laboratory Testing
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">All stool samples had a US Food and Drug Administration
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">(FDA)–approved </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff ic ile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">toxin immunoassay (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff ic ile
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Premier toxins A and B; Meridian Biosc iences) performed
<br>and reported clinically. Formed stools were rejected. Eligible
<br>samples also had 1 or more FDA-approved molecular </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diffi-
<br>cile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tests (Xpert </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C. difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">/Epi; Cepheid; and illumigene </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C.
<br>difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">; Meridian Biosciences) performed but not reported,
<br>allowing patients to be grouped by </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">toxin immuno-
<br>assay and PCR results as toxin immunoassay positive and
<br>PCR positive (Tox+/PCR+), Tox−/PCR+, or Tox−/PCR−. Addi-
<br>tional tests were performed to characterize the nature of the
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">colonization and host inflammatory response. The
<br>PCR-positive samples had toxin quantitated (xCELLigence
<br>System for Rea l-T ime Ce l lu lar Ana lys is , vers ion 2 ; ACEA
<br>Biosciences) and the concentration of </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">DNA deter-
<br>mined as a measure of bacterial load (Xpert </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C. difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">/Epi;
<br>Cepheid).</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">28-30 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">The Tox−/PCR+ samples were tested by a cell
<br>cytotoxin assay (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C. difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Tox-B; TechLab), the more sensi-
<br>tive historical standard for </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff ic ile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">toxin detection and
<br>diagnosis, to determine the number of samples that would
<br>have been positive if this test had been used instead of the
<br>toxin immunoassay. Culture was performed to recover </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C dif-
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">f icile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">isolates for ribotyping and verification of capac ity to
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">produce toxins. Lactoferrin was measured in PCR+ samples
<br>and random PCR− samp les as a marker of inflammat ion
<br>(Leuko EZ Vue; TechLab; and IBD-Scan; TechLab). Lactofer-
<br>rin results were classified as high if they exceeded the 95th
<br>percentile of results in PCR− patients. See the eMethods in
<br>the Supplement for additional details.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:1515px; width:227px; height:102px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Clinical Data Collection
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Diarrheal symptoms were verified at the time of </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff icile
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">testing. Patients were considered to have diarrhea if they had
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">at least 3 unformed bowel movements or at least 600 mL of
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">rectal or colostomy output recorded in the electronic health
<br>record (EHR) within 24 hours on the day of or before sample
<br>collection. Patients not meeting the threshold for diarrhea in
<br>the EHR had their nurse called to verify diarrheal status.
<br>Other data were obtained from laboratory, EHR, and adminis-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:1632px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:1632px; width:236px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted) JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:556px; top:1632px; width:14px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1793
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:1650px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:76px; top:904px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:959px; width:53px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:961px; width:227px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:1674px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:1674px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:1734px; width:612px; height:792px;"></span>
<div style="position:absolute; top:1734px;"><a name="3">Page 3</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:1764px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Research Original Investigation
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:404px; top:1764px; width:130px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:1794px; width:227px; height:23px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">trative databases. See the eMethods in the Supplement for
<br>additional details.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:1829px; width:227px; height:584px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Outcomes and Clinical Case Attribution
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">The primary outcome was duration of diarrhea for the 15-day
<br>period encompassing the day of sample collection (day 1) and
<br>up to 14 days of treatment. Secondary outcomes included rate
<br>of CDI-related complications (ie, megacolon, colectomy for ful-
<br>minant colitis, and intensive care unit [ICU] care related to CDI)
<br>and CDI-related deaths within 30 days. The CDI-related com-
<br>plications and deaths were analyzed separately to distin-
<br>guish patients with complicated CDI disease of the colon from
<br>patients with CDI as a contributing cause of death but not nec-
<br>essarily complicated CDI of the colon. Repeat </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tests
<br>and treatment were analyzed within 14 days of day 1 as an in-
<br>dication of ongoing clinical suspicion or empirical treatment
<br>for CDI in Tox−/PCR+ patients and to determine how many be-
<br>came positive with repeat testing. </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">Clostridium difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tests and
<br>treatment 15 to 30 days after day 1 were analyzed as a proxy
<br>for recurrent or prolonged CDI occurring after the initial treat-
<br>ment period. Ten or more days of metronidazole or oral van-
<br>comycin therapy was considered full treatment. Duration of
<br>diarrhea was determined from nurse-recorded stool counts and
<br>rectal or colostomy outputs in the EHR, excluding formed
<br>stools. Each day was categorized as a diarrhea day if at least 3
<br>unformed stools or at least 600 mL of fecal output was re-
<br>corded. Days with less stool output were categorized as a no-
<br>diarrhea day. Duration of diarrhea was the sum of days from
<br>day 1 to the last day with diarrhea, followed by 2 or more days
<br>without diarrhea. Cases of CDI-related megacolon and colec-
<br>tomies were identified by searching for patients with a proce-
<br>dure or billing code for abdominal radiology, colonoscopy, col-
<br>ectomy, or diagnosis of megacolon or pseudomembranous
<br>colitis within 30 days (eTable 1 in the Supplement). Clinical and
<br>surgical notes and radiology, endoscopy, and pathology re-
<br>ports were reviewed to confirm or exclude CDI-related mega-
<br>colon or colectomy. Partially treated complications diag-
<br>nosed before day 1 were excluded. Intensive care unit care
<br>related to CDI was determined as follows. First, patients lo-
<br>cated in or transferred into the ICU on day 1 (±1 day) were iden-
<br>tified. The ICU care was then determined to be CDI related (ie,
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">attributable to or contributed to by CDI) or unrelated by blinded
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">EHR review by 2 board-certified infectious diseases physi-
<br>cians (H.H.N., L.W.L., J.V.S., or S.H.C.). The physician adjudi-
<br>cators were blinded to PCR results but otherwise were pro-
<br>vided with all relevant clinical, procedural, diagnostic, and
<br>outcome information available in the EHR. Disagreements were
<br>resolved by a third infectious diseases physic ian (H.H.N.,
<br>L.W.L., J.V.S., or S.H.C.). Deaths were identified by discharge
<br>disposition codes and EHR review of PCR-positive patients with
<br>unknown mortality status at 30 days. Attribution of deaths as
<br>CDI related or unrelated was determined by blinded infec-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tious diseases physician EHR review (L.W.L., J.V.S., or S.H.C.)
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">in the same manner as for ICU care.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:2426px; width:227px; height:33px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Statistical Analysis
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Baseline data were summarized and tested for differences. The
<br>Kruskal-Wallis test was used for continuous variables except
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:306px; top:1794px; width:227px; height:160px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">for age, which was compared with an analysis of variance. For
<br>categorical variables, including outcomes, a χ</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">2 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">test or Fisher
<br>exact test was used. Kaplan-Meier estimates were used to show
<br>time to resolution of diarrhea for each group, with censoring
<br>of patients who were discharged or died during the follow-
<br>up, and compared with the log-rank test. A Cox proportional
<br>hazards model was used to estimate the effect of Tox+/PCR+
<br>or Tox−/PCR+ status compared with Tox−/PCR− status on the
<br>duration of diarrhea, adjusting for age, comorbidities, ICU sta-
<br>tus on day 1 (±1 day), prior antibiotic days, prior metronida-
<br>zole or oral vancomycin exposure, maximum white blood cell
<br>count on day 1 (±1 day), </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">ribotype, and fecal lactofer-
<br>rin level. See the eMethods in the Supplement for additional
<br>details.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:306px; top:1982px; width:227px; height:305px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:9px">Results
<br></span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Patient Cohort and Baseline Characteristics
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">An overv iew of the study design, patient cohort, and fol-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">low-up is shown in </span><span style="font-family: GNJKPN+GuardianTextEgypGR-Medium; font-size:8px">Figure 1</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">. In total, 1416 hospitalized adults
<br>were analyzed, including 131 Tox+/PCR+ patients (9.3%), 162
<br>Tox−/PCR+ patients (11.4%), and 1123 Tox−/PCR− patients
<br>(79.3%).
<br>The groups were similar in age, sex, number of comorbidi-
<br>ties, nonantibiotic medication exposures, and proportions with
<br>leukopenia, renal insuffic iency, and hypoalbuminemia ex-
<br>cept for fewer comorbidities in Tox−/PCR− patients (</span><span style="font-family: GNJKPN+GuardianTextEgypGR-Medium; font-size:8px">Table 1 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">and
<br>eTable 2 in the Supplement). However, the Tox+/PCR+ group
<br>had more prior antibiotic exposure, more patients with leu-
<br>kocytosis, and more diarrhea on day 1. In feces, Tox+/PCR+ pa-
<br>tients had an increased </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">bacterial load, higher toxin
<br>concentration, and greater frequency of hypervirulent </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C dif-
<br>ficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">strain than Tox−/PCR+ patients. Correspondingly, Tox+/
<br>PCR+ patients had significantly more fecal lactoferrin than
<br>Tox−/PCR+ patients, and 36.8% (43 of 117) had a lactoferrin level
<br>greater than the 95th percentile of Tox−/PCR− patients. In con-
<br>trast, few Tox−/PCR+ patients (13.4% [19 of 142]) had a lacto-
<br>ferrin level above the 95th percentile of Tox−/PCR− patients,
<br>and 79.0% (15 of 19) of these patients had an alternative ex-
<br>planation for fecal inflammation, a previous diagnosis of CDI,
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">or anti–</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff icile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">treatment before testing (eTable 3 in the
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Supplement).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:306px; top:2300px; width:227px; height:160px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Duration of Diarrhea
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">The Tox+/PCR+ patients had a longer duration of diarrhea than
<br>Tox−/PCR+ patients and Tox−/PCR− patients (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">&lt; .001) and had
<br>a greater risk of diarrhea during the follow-up (</span><span style="font-family: GNJKPN+GuardianTextEgypGR-Medium; font-size:8px">Figure 2 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">and
<br></span><span style="font-family: GNJKPN+GuardianTextEgypGR-Medium; font-size:8px">Table 2</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">). In contrast, Tox−/PCR+ patients and Tox−/PCR− pa-
<br>tients had a similar risk of diarrhea on most days.
<br>In the multivariable model, Tox+/PCR+ status had the
<br>strongest effect on duration of diarrhea, decreasing the prob-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">ability of diarrhea being resolved by 37% each day relative to
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">the Tox−/PCR− reference group (hazard ratio, 0.63; 95% CI,
<br>0.48-0.83). Age, white blood cell count, and lactoferrin level
<br>were also significant predictors of duration of diarrhea, but their
<br>relative contribution was small (≤2% each) (eTable 4 in the
<br>Supplement). The Tox−/PCR+ status and pretest exposure to
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:40px; top:2474px; width:14px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1794
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:2474px; width:195px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:268px; top:2474px; width:35px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:458px; top:2474px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:2492px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:67px; top:1746px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:306px; top:1977px; width:53px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:306px; top:1979px; width:227px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:2516px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:2516px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:2576px; width:612px; height:792px;"></span>
<div style="position:absolute; top:2576px;"><a name="4">Page 4</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:2606px; width:130px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:448px; top:2606px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Original Investigation Research
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:2643px; width:176px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Figure 1. Flow of Patients Through Testing and Follow-up
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:215px; top:2665px; width:128px; height:16px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">1467 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Eligible patients (hospitalized adults tested
<br>for </span><span style="font-family: GuardianAgateSans1-RegularIt; font-size:5px">C difficile</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px"> ≥72 h after admission)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:304px; top:2695px; width:86px; height:25px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">42 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Excluded
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">41 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Discharged before testing
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">1 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Missed
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:220px; top:2735px; width:119px; height:16px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">1425 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Tested by </span><span style="font-family: GuardianAgateSans1-RegularIt; font-size:5px">C difficile</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px"> toxin immunoassay,
<br>PCR, and culture
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:302px; top:2765px; width:88px; height:9px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">9 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Excluded (Tox–/PCR–/Culture+)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:249px; top:2789px; width:61px; height:9px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">1416 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Included in study
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:160px; top:2823px; width:59px; height:9px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">293 </span><span style="font-family: GuardianAgateSans1-RegularIt; font-size:5px">C difficile</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px"> positive
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:337px; top:2823px; width:65px; height:9px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">1123 </span><span style="font-family: GuardianAgateSans1-RegularIt; font-size:5px">C difficile</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px"> negative
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:108px; top:2858px; width:44px; height:9px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">131 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Tox+/PCR+</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:4px">a
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:226px; top:2858px; width:47px; height:9px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">162 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Tox–/PCR+</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:4px">a,b
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:344px; top:2858px; width:49px; height:9px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">1123 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Tox–/PCR–</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:4px">a,c
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:100px; top:2879px; width:60px; height:27px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">Baseline
<br>115 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">16 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">&lt;3 Stools per 24 h
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:91px; top:2919px; width:78px; height:43px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">15-Day follow-up (diarrhea)
<br>109 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Resolved
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">6 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">15 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Discharged with diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">1 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Died with diarrhea
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:89px; top:2974px; width:81px; height:35px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">30-Day follow-up (mortality)
<br>96 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Alive
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">14 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Died
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">21 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Unknown
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:219px; top:2879px; width:60px; height:27px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">Baseline
<br>121 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">41 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">&lt;3 Stools per 24 h
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:210px; top:2919px; width:78px; height:43px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">15-Day follow-up (diarrhea)
<br>148 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Resolved
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">2 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">12 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Discharged with diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">0 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Died with diarrhea
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:209px; top:2974px; width:81px; height:35px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">30-Day follow-up (mortality)
<br>120 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Alive
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">23 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Died
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">19 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Unknown
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:339px; top:2879px; width:60px; height:27px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">Baseline
<br>773 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">350 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">&lt;3 Stools per 24 h
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:329px; top:2919px; width:81px; height:43px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">15-Day follow-up (diarrhea)
<br>1048 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Resolved
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">16 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">57 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Discharged with diarrhea
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">2 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Died with diarrhea
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:328px; top:2974px; width:81px; height:35px;"><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">30-Day follow-up (mortality)
<br>751 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Alive
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">98 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Died
<br></span><span style="font-family: GNJLCN+GuardianAgateSans1GR-Bold; font-size:5px">274 </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Unknown
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:435px; top:2853px; width:107px; height:169px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Tox+/PCR+ indicates </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin immunoassay positive
<br>and polymerase chain reaction
<br>positive; Tox−/PCR+, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin
<br>immunoassay negative and
<br>polymerase chain reaction positive;
<br>and Tox−/PCR−, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin
<br>immunoassay negative and
<br>polymerase chain reaction negative.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">a </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">test group based
<br>on US Food and Drug
<br>Administration–approved toxin
<br>immunoassay and polymerase chain
<br>reaction results.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">b </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Includes one patient with
<br>false-positive immunoassay.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">c </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Includes 20 patients with
<br>false-positive immunoassay.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:3049px; width:227px; height:23px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">metronidazole or oral vancomycin were not significant pre-
<br>dictors in the multivariable model.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:3084px; width:227px; height:217px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">CDI-Related Complications and Mortality Within 30 Days
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">The frequency of CDI-related complications (ie, megacolon, col-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">ectomy for fulminant colitis, and ICU care related to CDI) and
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">deaths is summarized in </span><span style="font-family: GNJKPN+GuardianTextEgypGR-Medium; font-size:8px">Table 3</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">. The Tox+/PCR+ patients had
<br>more CDI-related complications than Tox−/PCR+ patients and
<br>Tox−/PCR− patients (10 [7.6%] of 131 vs 0 [0%] of 162 vs 3 [0.3%]
<br>of 1123, </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">&lt; .001). In contrast, the rate of CDI-related complica-
<br>tions was similar between Tox−/PCR+ patients and Tox−/PCR−
<br>patients (0% vs 0.3%, </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">&gt; .99). The Tox+/PCR+ patients also had
<br>more CDI-related deaths than Tox−/PCR+ patients and Tox−/
<br>PCR− patients (11 [8.4%] of 131 vs 1 [0.6%] of 162 vs 0 [0%] of 1123,
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">&lt; .001) while the rate was similar between Tox−/PCR+ pa-
<br>tients and Tox−/PCR− patients (0.6% vs 0%, </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .13). Two deaths
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">in the Tox+/PCR+ group were directly attributable to CDI, and 9
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">had CDI as a contributing factor. One Tox−/PCR+ patient (pa-
<br>tient 1641 in eTable 3 in the Supplement) had an uncompli-
<br>cated, recurrent CDI that resolved before care was withdrawn
<br>for severe underlying illness, but CDI was considered a contrib-
<br>uting factor to death.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:3050px; width:227px; height:171px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Repeat </span><span style="font-family: GNJKIK+GuardianSans-MediumIt; font-size:8px">C difficile </span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Testing and Treatment Within 14 Days
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Repeat </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">testing and treatment within 14 days of day 1
<br>was analyzed as an indication of ongoing clinical suspicion or
<br>empirical treatment for CDI in Tox−/PCR+ patients (Table 3). Dur-
<br>ing this period, 61 Tox−/PCR+ patients (37.7%) were retested,
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">and 13 (8.0%) had toxins detected (mean time to positive re-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">sult, 5.7 days; 95% CI, 3.2-8.2 days). None of these patients de-
<br>veloped a </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">–related complication. However, one pa-
<br>tient (patient 1641 in eTable 3 in the Supplement) had CDI that
<br>was considered a contributing factor to death, although symp-
<br>toms had resolved before care was withdrawn for other rea-
<br>sons. During the same period, most Tox−/PCR+ patients (59.3%
<br>[96 of 162]) received no treatment, 45 patients (27.8% [45 of 162])
<br>received partial treatment (1-9 days), and 21 patients (13.0% [21
<br>of 162]) received the equivalent of full treatment (≥10 days).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:3233px; width:227px; height:68px;"><span style="font-family: GNJKIK+GuardianSans-MediumIt; font-size:8px">Clostridium difficile </span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Testing and Treatment
<br></span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Between 15 and 30 Days
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">Clostridium difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tests and treatment 15 to 30 days after day
<br>1 were analyzed as a proxy for recurrent or prolonged CDI
<br>(Table 3). During this period, Tox+/PCR+ patients were re-
<br>tested almost twice as often as Tox−/PCR+ patients (19.8% vs
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:3316px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3316px; width:236px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted) JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:556px; top:3316px; width:14px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1795
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:3334px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:76px; top:2588px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2641px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2656px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:369px; top:2965px; width:0px; height:6px;"></span>
<span style="position:absolute; border: black 1px solid; left:368px; top:2970px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:250px; top:2965px; width:0px; height:6px;"></span>
<span style="position:absolute; border: black 1px solid; left:248px; top:2970px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:130px; top:2965px; width:0px; height:6px;"></span>
<span style="position:absolute; border: black 1px solid; left:129px; top:2970px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:208px; top:2664px; width:143px; height:19px;"></span>
<span style="position:absolute; border: black 1px solid; left:208px; top:2664px; width:143px; height:19px;"></span>
<span style="position:absolute; border: black 1px solid; left:208px; top:2734px; width:143px; height:19px;"></span>
<span style="position:absolute; border: black 1px solid; left:208px; top:2734px; width:143px; height:19px;"></span>
<span style="position:absolute; border: black 1px solid; left:280px; top:2709px; width:11px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:290px; top:2708px; width:3px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:294px; top:2695px; width:104px; height:28px;"></span>
<span style="position:absolute; border: black 1px solid; left:294px; top:2695px; width:104px; height:28px;"></span>
<span style="position:absolute; border: black 1px solid; left:280px; top:2771px; width:11px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:290px; top:2770px; width:3px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:294px; top:2765px; width:104px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:294px; top:2765px; width:104px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:280px; top:2684px; width:0px; height:47px;"></span>
<span style="position:absolute; border: black 1px solid; left:278px; top:2731px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:280px; top:2754px; width:0px; height:31px;"></span>
<span style="position:absolute; border: black 1px solid; left:278px; top:2785px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:280px; top:2800px; width:0px; height:11px;"></span>
<span style="position:absolute; border: black 1px solid; left:369px; top:2910px; width:0px; height:6px;"></span>
<span style="position:absolute; border: black 1px solid; left:368px; top:2915px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:369px; top:2868px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:368px; top:2875px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:369px; top:2832px; width:0px; height:23px;"></span>
<span style="position:absolute; border: black 1px solid; left:368px; top:2854px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:369px; top:2812px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:368px; top:2819px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:190px; top:2812px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:188px; top:2819px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:190px; top:2835px; width:0px; height:11px;"></span>
<span style="position:absolute; border: black 1px solid; left:136px; top:2823px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:136px; top:2823px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2823px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2823px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:250px; top:2910px; width:0px; height:6px;"></span>
<span style="position:absolute; border: black 1px solid; left:248px; top:2915px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:250px; top:2868px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:248px; top:2875px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:250px; top:2846px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:248px; top:2854px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:130px; top:2910px; width:0px; height:6px;"></span>
<span style="position:absolute; border: black 1px solid; left:129px; top:2915px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:130px; top:2868px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:129px; top:2875px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2974px; width:107px; height:38px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2974px; width:107px; height:38px;"></span>
<span style="position:absolute; border: black 1px solid; left:196px; top:2974px; width:107px; height:38px;"></span>
<span style="position:absolute; border: black 1px solid; left:196px; top:2974px; width:107px; height:38px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2974px; width:107px; height:38px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2974px; width:107px; height:38px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2879px; width:107px; height:30px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2879px; width:107px; height:30px;"></span>
<span style="position:absolute; border: black 1px solid; left:196px; top:2879px; width:107px; height:30px;"></span>
<span style="position:absolute; border: black 1px solid; left:196px; top:2879px; width:107px; height:30px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2879px; width:107px; height:30px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2879px; width:107px; height:30px;"></span>
<span style="position:absolute; border: black 1px solid; left:130px; top:2846px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:129px; top:2854px; width:2px; height:3px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2857px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2857px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:196px; top:2857px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:196px; top:2857px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2857px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2857px; width:107px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2919px; width:107px; height:46px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:2919px; width:107px; height:46px;"></span>
<span style="position:absolute; border: black 1px solid; left:196px; top:2919px; width:107px; height:46px;"></span>
<span style="position:absolute; border: black 1px solid; left:196px; top:2919px; width:107px; height:46px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2919px; width:107px; height:46px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:2919px; width:107px; height:46px;"></span>
<span style="position:absolute; border: black 1px solid; left:130px; top:2846px; width:119px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:190px; top:2812px; width:179px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:208px; top:2788px; width:143px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:208px; top:2788px; width:143px; height:12px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:3021px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:3358px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:3358px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:3418px; width:612px; height:792px;"></span>
<div style="position:absolute; top:3418px;"><a name="5">Page 5</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:3448px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Research Original Investigation
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:404px; top:3448px; width:130px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:3485px; width:280px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Table 1. Baseline Characteristics of the Study Population by </span><span style="font-family: GNJKIK+GuardianSans-MediumIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Test Group
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:70px; top:3519px; width:96px; height:457px;"><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Characteristic
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Age, median (IQR), y
<br>Female sex, No. (%)
<br>Comorbidities, median (IQR)
<br>APR-DRG risk of mortality
<br>subclass 3 or 4, No. (%)
<br>Intensive care unit care on day 1
<br>±1 d, No. (%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Hospital days before day 1,
<br>median (IQR)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Admitted from health care
<br>facility, No. (%)
<br></span><span style="font-family: GNJLEB+GuardianAgateSans1D-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">positive within 90 d
<br>before day 1</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Antibiotic days within 90 d before
<br>day 1, median (IQR)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Other diarrheal or
<br>gastrointestinal inflammatory
<br>process, No. (%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">f
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Metronidazole or oral
<br>vancomycin within 48 h before
<br>day 1, No. (%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">WBC count ≥15 000 cells/μL on
<br>day 1 ±1 d, No./total No. tested
<br>(%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">WBC count &lt;4000 cells/μL on day
<br>1 ±1 d, No./total No. tested (%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Creatinine level &gt;1.5 mg/dL on
<br>day 1 ±1 d, No./total No. tested
<br>(%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Albumin level &lt;2.5 g/dL on day 1
<br>±1 d, No./total No. tested (%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Diarrhea present on day 1 ±1 d,
<br>No. (%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Stool count on day 1, median
<br>(IQR)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">e
<br></span><span style="font-family: GNJLEB+GuardianAgateSans1D-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">toxin B, median (IQR),
<br>ng/mL
<br>Hypervirulent </span><span style="font-family: GNJLEB+GuardianAgateSans1D-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">ribotype
<br>RT027/078, No. (%)
<br></span><span style="font-family: GNJLEB+GuardianAgateSans1D-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">binary toxin positive,
<br>No. (%)
<br>Log</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">10 </span><span style="font-family: GNJLEB+GuardianAgateSans1D-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">DNA copies/mL,
<br>median (IQR)
<br>Fecal lactoferrin level, median
<br>(IQR), μg/mL,
<br>Normal lactoferrin level,
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">No./total No. tested</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">g
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">High lactoferrin level, No./total
<br>No. tested</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">h
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:172px; top:3501px; width:51px; height:74px;"><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">C difficile </span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Positive
<br>Tox+/PCR+</span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:3px">b
<br></span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">(n = 131)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">64 (52-71)
<br>64 (48.9)
<br>4 (2-6)
<br>104 (79.4)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:243px; top:3512px; width:38px; height:63px;"><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Tox−/PCR+</span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:3px">b,c
<br></span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">(n = 162)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">58 (48-68)
<br>83 (51.2)
<br>4 (2-5)
<br>128 (79.0)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3501px; width:54px; height:74px;"><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">C difficile </span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Negative
<br>Tox−/PCR−</span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:3px">b,d
<br></span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">(n = 1123)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">59 (47-71)
<br>530 (47.2)
<br>3 (2-5)
<br>787 (70.1)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3519px; width:23px; height:55px;"><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">P </span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Value</span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:3px">a
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.12
<br>.61
<br>.01
<br>.008
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3585px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">30 (22.9)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3603px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">10 (6-24)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3621px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">40 (30.5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:180px; top:3639px; width:20px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">5 (3.8)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3658px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">16 (7-32)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:180px; top:3676px; width:20px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">8 (6.1)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:180px; top:3702px; width:20px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">3 (2.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3585px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">57 (35.2)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3585px; width:31px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">435 (38.7)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:250px; top:3603px; width:25px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">8 (5-12)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:3603px; width:25px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">8 (5-12)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3621px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">34 (21.0)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3621px; width:31px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">160 (14.2)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3639px; width:24px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">10 (6.2)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3658px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">10 (4-27)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:311px; top:3639px; width:24px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">13 (1.2)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:3658px; width:25px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">8 (4-18)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3676px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">27 (16.7)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3676px; width:31px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">161 (14.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3702px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">32 (19.8)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3702px; width:31px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">184 (16.4)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3727px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">54/129 (41.9)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3727px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">50/154 (32.5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3727px; width:50px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">323/1101 (29.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3753px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">20/129 (15.5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3753px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">32/154 (20.8)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3753px; width:50px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">200/1101 (18.2)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3771px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">36/127 (28.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3771px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">45/156 (28.8)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3771px; width:50px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">297/1102 (27.0)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3797px; width:38px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">29/48 (60.4)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3797px; width:38px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">50/70 (71.4)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3797px; width:46px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">318/475 (66.9)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:172px; top:3815px; width:31px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">121 (92.4)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:243px; top:3815px; width:31px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">143 (88.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3815px; width:31px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">927 (82.5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:180px; top:3833px; width:21px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">5 (3-6)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:250px; top:3833px; width:21px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">3 (2-5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:3833px; width:21px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">3 (2-5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:172px; top:3851px; width:65px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">640.8 (172.5-1194.0)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:250px; top:3851px; width:38px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">1.1 (0.3-2.5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3870px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">68 (51.9)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3888px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">71 (54.2)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3870px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">39 (24.1)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3888px; width:28px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">45 (27.8)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:180px; top:3906px; width:38px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">7.3 (6.6-7.7)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:250px; top:3906px; width:38px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">4.9 (4.4-6.2)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3851px; width:8px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">NA
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3870px; width:8px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">NA
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3888px; width:8px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">NA
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:3906px; width:8px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">NA
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3924px; width:50px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">37.7 (8.8-261.5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3924px; width:46px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">20.1 (5.0-50.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:3924px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">7.8 (0.5-32.6)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3943px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">25/117 (21.4)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3943px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">44/142 (31.0)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:311px; top:3943px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">89/188 (47.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:3961px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">43/117 (36.8)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:247px; top:3961px; width:42px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">19/142 (13.4)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:3961px; width:34px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">9/188 (4.8)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:389px; top:3585px; width:13px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.002
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3603px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3621px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3639px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3658px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:389px; top:3676px; width:9px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.02
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3702px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:389px; top:3727px; width:9px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.01
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:389px; top:3753px; width:9px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.52
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:389px; top:3771px; width:9px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.85
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:389px; top:3797px; width:9px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.46
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:389px; top:3815px; width:13px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.004
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3833px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3851px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3870px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3888px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3906px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3924px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3943px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:385px; top:3961px; width:17px; height:8px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:426px; top:3518px; width:107px; height:462px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Abbreviations: APR-DRG, all-patient
<br>refined diagnosis-related group;
<br>IQR, interquartile range; NA, not
<br>applicable; Tox+/PCR+, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin immunoassay positive and
<br>polymerase chain reaction positive;
<br>Tox−/PCR+, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin
<br>immunoassay negative and
<br>polymerase chain reaction positive;
<br>Tox−/PCR−, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin
<br>immunoassay negative and
<br>polymerase chain reaction negative;
<br>WBC, white blood cell.
<br>SI conversion factors: To convert
<br>WBC count to ×10</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">9</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">/L, multiply by
<br>0.001; to convert creatinine level to
<br>micromoles per liter, multiply by
<br>88.4; to convert albumin level to
<br>grams per liter, multiply by 10.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">a </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">value for significance across 3
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">groups except for characteristics
<br>not applicable to Tox−/PCR− group.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">b </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">test group based
<br>on US Food and Drug
<br>Administration–approved toxin
<br>immunoassay and PCR results.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">c </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Includes one patient with
<br>false-positive toxin immunoassay.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">d </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Includes 20 patients with
<br>false-positive toxin immunoassay.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">e </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Day 1 is the day of sample collection
<br>for the </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin test.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">f </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Includes inflammatory bowel
<br>diseases, functional diarrheal
<br>disorders, diverticulitis,
<br>appendicitis, ischemic colitis, other
<br>infectious or noninfectious
<br>enterocolitis, graft-vs-host disease,
<br>and peritoneal, mesenteric, or
<br>retroperitoneal infections.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">g </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Normal fecal lactoferrin level
<br>defined as within the upper limit of
<br>a healthy person’s reference range
<br>per the manufacturer’s package
<br>insert.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">h </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">High fecal lactoferrin level defined
<br>as exceeding the 95th percentile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">fecal lactoferrin level in Tox−/PCR−
<br>patients (&gt;89.05 μg /mL).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:3994px; width:227px; height:46px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">11.1%, </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .04) and were positive 3 times more often (10.7% vs
<br>3.1%, </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">&lt; .001). During the same period, most Tox−/PCR+ pa-
<br>tients (78.4% [127 of 162]) received no treatment, while 13 pa-
<br>tients (8.0% [13 of 162]) received treatment for at least 10 days.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:4053px; width:227px; height:91px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Additional Analyses to Evaluate the Robustness
<br>of the Study Findings
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Outcome differences between the Tox−/PCR+ and Tox+/PCR+
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">groups remained significant when comparisons were limited
<br>to the subgroup of Tox−/PCR+ patients who received full or par-
<br>tial treatment within 14 days (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .04 for time to resolution of
<br>diarrhea and </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .004 for CDI-related complication or death)
<br>or no treatment (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .003 for time to resolution of diarrhea and
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:306px; top:3994px; width:227px; height:149px;"><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">&lt; .001 for CDI-related complication or death). No signifi-
<br>cant outcome differences were observed between the Tox−/
<br>PCR− group and individual Tox−/PCR+ subgroups with or with-
<br>out treatment.
<br>If the historical cell cytotoxin assay had been used for di-
<br>agnosis instead of a toxin immunoassay, 48 additional Tox−/
<br>PCR+ patients (29.6%) would have been reported positive.
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">However, this subgroup had a low toxin concentration (me-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">dian, 10 ng /mL; interquartile range, 2-81 ng /mL) and out-
<br>comes that were similar to cell cytotoxin–negative Tox−/
<br>PCR+ patients (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .47 for time to resolution of diarrhea and
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .30 for CDI-related complication or death), with no differ-
<br>ence in treatment (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .61), and better than Tox+/PCR+ pa-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:40px; top:4158px; width:14px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1796
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:4158px; width:195px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:268px; top:4158px; width:35px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:458px; top:4158px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:4176px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:67px; top:3484px; width:347px; height:13px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3498px; width:102px; height:31px;"></span>
<span style="position:absolute; border: black 1px solid; left:169px; top:3498px; width:212px; height:13px;"></span>
<span style="position:absolute; border: black 1px solid; left:382px; top:3498px; width:32px; height:31px;"></span>
<span style="position:absolute; border: black 1px solid; left:169px; top:3512px; width:212px; height:18px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3430px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3483px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3498px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:172px; top:3512px; width:128px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:307px; top:3512px; width:71px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3530px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3542px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3554px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3566px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3584px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3602px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3620px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3639px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3657px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3675px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3701px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3726px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3752px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3770px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3796px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3814px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3832px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3851px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3869px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3887px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3905px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3924px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3942px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3960px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3978px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:3978px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:4200px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:4200px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:4260px; width:612px; height:792px;"></span>
<div style="position:absolute; top:4260px;"><a name="6">Page 6</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:4290px; width:130px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:448px; top:4290px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Original Investigation Research
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:4320px; width:227px; height:23px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tients (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">&lt; .001 for time to resolution of diarrhea and </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">= .03
<br>for CDI-related complication or death).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:4370px; width:227px; height:53px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:9px">Discussion
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">This study addresses an important question for physicians,
<br>hospitals, and policy makers: do toxin-negative patients with
<br>a positive </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff icile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">PCR test result require treatment? To
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:4442px; width:208px; height:19px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Figure 2. Kaplan-Meier Curves of Time to Resolution of Diarrhea by
<br></span><span style="font-family: GNJKIK+GuardianSans-MediumIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Test Group
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:4320px; width:227px; height:424px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">answer this question, we prospectively tested 1416 hospital-
<br>ized patients with FDA-approved PCR tests while maintain-
<br>ing our existing toxin test for clinical diagnosis to determine
<br>the natural history of toxin-negative patients with positive
<br>PCR results. We found that 55.3% (162 of 293) of patients
<br>with a positive </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">PCR test result lacked toxin by the
<br>clinical toxin immunoassay test and had outcomes that were
<br>comparable to patients w ith no </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff icile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">detected. These
<br>Tox−/PCR+ patients had milder symptoms at the time of test-
<br>ing and a shorter duration of diarrhea than toxin-positive
<br>patients. In total, 58.7% (95 of 162) were never retested, and
<br>only 13.0% (21 of 162) received the equivalent of a full course
<br>of treatment. Repeat analyses with the treated Tox−/PCR+
<br>patients removed did not change our conclusions. Overall, 18
<br>of 19 </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff ic ile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">–related complications and deaths (94.7%)
<br>occurred in toxin-positive patients. Only one of 162 toxin-
<br>negative patients (0.6%) was considered to have CDI as a con-
<br>tributing factor to death.
<br>Our findings are consistent with the conventional view that
<br>CDI is a toxin-mediated inflammatory disease preceded by an-
<br>tibiotic exposure and </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">overgrowth.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">3 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Toxin-negative
<br>patients had less antibiotic exposure, </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">DNA, and in-
<br>flammation and manifested milder symptoms and no compli-
<br>cations, despite minimal or no treatment. These findings
<br>strongly suggest that most patients with negative toxin test re-
<br>sults and </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">detected by PCR do not need treatment for
<br>CDI. We suspect that most of these patients were colonized with
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">and had another cause of diarrhea. This hypothesis
<br>is supported by studies</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">22-26,31 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">showing that </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">coloni-
<br>zation and immunity are common in hospitalized patients and
<br>most nosocomial diarrhea is noninfectious. It is possible that
<br>some toxin-negative patients have mild or early infection be-
<br>cause clinical toxin tests can miss toxin at low concentra-
<br>tions, and occasional toxin-negative patients become posi-
<br>t ive o n r e p e a t t e s t i ng . </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">3 , 1 0 , 1 8 , 3 2 - 3 5 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">C o r r e sp ond ing l y, we
<br>detected toxin in 29.6% (48 of 162) of Tox−/PCR+ patients by
<br>the historical cell cytotoxin assay, and 8.0% (13 of 162) of
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:265px; top:4484px; width:27px; height:22px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Tox+/PCR+
<br>Tox–/PCR+
<br>Tox–/PCR–
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:287px; top:4587px; width:6px; height:7px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">14
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:287px; top:4616px; width:6px; height:22px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">8
<br>2
<br>23
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:109px; top:4472px; width:8px; height:7px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">1.0
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:109px; top:4494px; width:8px; height:7px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">0.8
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:109px; top:4516px; width:8px; height:7px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">0.6
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:109px; top:4537px; width:8px; height:7px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">0.4
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:109px; top:4559px; width:8px; height:7px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">0.2
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:98px; top:4497px; width:8px; height:66px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">a
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">e
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">h
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:1px">r
<br>r
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">a
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:1px">i
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">D
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:0px"> 
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">h
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:1px">t
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:1px">i
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">W
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:0px"> 
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">n
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">o
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:1px">i
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:1px">t
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:1px">r
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">o
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">p
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">o
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:1px">r
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:2px">P
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:114px; top:4581px; width:3px; height:7px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">0
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:119px; top:4587px; width:3px; height:7px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">0
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:145px; top:4587px; width:127px; height:17px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">10
<br>7
<br>5
<br>3
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">Duration of Diarrhea, Including Day of Testing, d
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:4608px; width:33px; height:30px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">No. at risk
<br>Tox+/PCR+
<br>Tox–/PCR+
<br>Tox–/PCR–
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:114px; top:4616px; width:13px; height:22px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">131
<br>162
<br>1123
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:152px; top:4616px; width:9px; height:22px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">62
<br>60
<br>328
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:176px; top:4616px; width:9px; height:22px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">41
<br>29
<br>172
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:202px; top:4616px; width:6px; height:22px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">29
<br>21
<br>99
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:238px; top:4616px; width:6px; height:22px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:5px">25
<br>10
<br>42
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:4649px; width:226px; height:89px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">The median duration of diarrhea for patients with at least 1 day was 3 days
<br>(interquartile range, 1-6 days) for Tox+/PCR+ (121 of 131), 2 days (interquartile
<br>range, 1-4 days) for Tox−/PCR+, and 2 days (interquartile range, 1-3 days) for
<br>Tox−/PCR− (927 of 1123) (</span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">&lt; .001). Log-rank </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">values are </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">&lt; .001 for all groups,
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">= .003 for Tox+/PCR+ vs Tox−/PCR+, (143 of 162) </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">&lt; .001 for Tox+/PCR+ vs
<br>Tox−/PCR−, and </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">&lt; .001 for Tox−/PCR+ vs Tox−/PCR−. Tox+/PCR+ indicates </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C
<br>difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin immunoassay positive and polymerase chain reaction positive;
<br>Tox−/PCR+, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin immunoassay negative and polymerase chain
<br>reaction positive; Tox−/PCR−, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin immunoassay negative and
<br>polymerase chain reaction negative.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:4765px; width:161px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Table 2. Relative Risk (95% CI) of Diarrhea Each Day
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:79px; top:4794px; width:10px; height:187px;"><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Day
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">1
<br>2
<br>3
<br>4
<br>5
<br>6
<br>7
<br>8
<br>9
<br>10
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">11
<br>12
<br>13
<br>14
<br>15
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:119px; top:4782px; width:72px; height:199px;"><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Comparison
<br></span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Tox+/PCR+ vs Tox−/PCR+
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">1.05 (0.97-1.13)
<br>1.27 (1.03-1.56)
<br>1.28 (0.98-1.67)
<br>1.51 (1.07-02.13)
<br>1.75 (1.15-2.65)
<br>1.88 (1.17-3.02)
<br>1.71 (1.02-2.85)
<br>2.30 (1.25-4.22)
<br>3.09 (1.54-6.20)
<br>3.18 (1.37-7.38)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">3.18 (1.37-7.38)
<br>2.89 (1.14-7.30)
<br>3.09 (0.99-9.63)
<br>4.95 (1.07-22.90)
<br>3.71 (0.76-18.08)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:227px; top:4794px; width:72px; height:187px;"><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Tox+/PCR+ vs Tox−/PCR−
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">1.12 (1.06-1.18)
<br>1.46 (1.29-1.73)
<br>1.62 (1.32-1.98)
<br>1.87 (1.46-2.40)
<br>2.04 (1.53-2.73)
<br>2.31 (1.67-3.20)
<br>2.51 (1.73-3.64)
<br>2.72 (1.82-4.06)
<br>3.90 (2.52-6.03)
<br>3.67 (2.18-6.19)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">4.06 (2.39-6.90)
<br>3.64 (2.00-6.62)
<br>3.30 (1.63-6.68)
<br>2.98 (1.36-6.53)
<br>3.22 (1.28-8.07)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:336px; top:4794px; width:72px; height:187px;"><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Tox−/PCR+ vs Tox−/PCR−
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">1.07 (1.01-1.14)
<br>1.18 (0.99-1.40)
<br>1.27 (1.02-1.58)
<br>1.24 (0.93-1.66)
<br>1.17 (0.82-1.67)
<br>1.23 (0.81-1.85)
<br>1.47 (0.95-2.29)
<br>1.18 (0.69-2.04)
<br>1.26 (0.66-2.42)
<br>1.16 (0.53-2.53)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">1.28 (0.58-2.81)
<br>1.26 (0.54-2.96)
<br>1.07 (0.38-3.02)
<br>0.60 (0.14-2.53)
<br>0.87 (0.20-3.73)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:435px; top:4896px; width:102px; height:89px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Abbreviations: Tox+/PCR+,
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin
<br>immunoassay positive and
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">polymerase chain reaction positive;
<br>Tox−/PCR+, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin
<br>immunoassay negative and
<br>polymerase chain reaction positive;
<br>Tox−/PCR−, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin
<br>immunoassay negative and
<br>polymerase chain reaction negative.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:5000px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:5000px; width:236px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted) JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:556px; top:5000px; width:13px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1797
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:5018px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:76px; top:4765px; width:347px; height:13px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4778px; width:39px; height:25px;"></span>
<span style="position:absolute; border: black 1px solid; left:116px; top:4778px; width:307px; height:13px;"></span>
<span style="position:absolute; border: black 1px solid; left:116px; top:4792px; width:307px; height:11px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4272px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4366px; width:53px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4368px; width:227px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4441px; width:227px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4465px; width:227px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:120px; top:4476px; width:181px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:118px; top:4476px; width:2px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:120px; top:4498px; width:181px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:118px; top:4498px; width:1px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:120px; top:4520px; width:181px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:118px; top:4520px; width:1px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:120px; top:4541px; width:181px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:118px; top:4541px; width:1px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:120px; top:4563px; width:181px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:118px; top:4563px; width:1px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:120px; top:4476px; width:181px; height:109px;"></span>
<span style="position:absolute; border: black 1px solid; left:118px; top:4585px; width:1px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:120px; top:4585px; width:0px; height:1px;"></span>
<span style="position:absolute; border: black 1px solid; left:157px; top:4585px; width:0px; height:1px;"></span>
<span style="position:absolute; border: black 1px solid; left:181px; top:4585px; width:0px; height:1px;"></span>
<span style="position:absolute; border: black 1px solid; left:205px; top:4585px; width:0px; height:1px;"></span>
<span style="position:absolute; border: black 1px solid; left:241px; top:4585px; width:0px; height:1px;"></span>
<span style="position:absolute; border: black 1px solid; left:290px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:302px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:253px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:229px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:217px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:193px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:169px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:144px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:132px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:266px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:278px; top:4585px; width:0px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:241px; top:4482px; width:54px; height:27px;"></span>
<span style="position:absolute; border: black 1px solid; left:241px; top:4482px; width:54px; height:27px;"></span>
<span style="position:absolute; border: black 1px solid; left:296px; top:4509px; width:0px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:245px; top:4488px; width:17px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:245px; top:4495px; width:17px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:245px; top:4503px; width:17px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:121px; top:4476px; width:182px; height:99px;"></span>
<span style="position:absolute; border: black 1px solid; left:301px; top:4574px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:289px; top:4574px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:276px; top:4573px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:228px; top:4562px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:204px; top:4555px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:192px; top:4552px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:179px; top:4548px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:167px; top:4544px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:155px; top:4538px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:143px; top:4529px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:121px; top:4476px; width:181px; height:107px;"></span>
<span style="position:absolute; border: black 1px solid; left:301px; top:4582px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:216px; top:4574px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:204px; top:4571px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:180px; top:4564px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:167px; top:4560px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:155px; top:4553px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:143px; top:4540px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:131px; top:4528px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:121px; top:4476px; width:181px; height:106px;"></span>
<span style="position:absolute; border: black 1px solid; left:301px; top:4581px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:289px; top:4581px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:276px; top:4580px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:264px; top:4580px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:240px; top:4578px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:228px; top:4578px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:216px; top:4576px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:204px; top:4574px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:192px; top:4572px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:180px; top:4569px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:167px; top:4565px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:155px; top:4559px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:143px; top:4550px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:131px; top:4537px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:131px; top:4513px; width:2px; height:2px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4646px; width:227px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4744px; width:227px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4764px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4778px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:119px; top:4792px; width:304px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4804px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4816px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4828px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4840px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4852px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4864px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4876px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4888px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4900px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4912px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4924px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4936px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4948px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4960px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4972px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4984px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:4984px; width:347px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:5042px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:5042px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:5102px; width:612px; height:792px;"></span>
<div style="position:absolute; top:5102px;"><a name="7">Page 7</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:5132px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Research Original Investigation
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:404px; top:5132px; width:130px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:5169px; width:254px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Table 3. Nondiarrheal Outcomes and Treatment by </span><span style="font-family: GNJKIK+GuardianSans-MediumIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Test Group
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:5185px; width:226px; height:367px;"><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">C difficile </span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Positive
<br>Tox+/PCR+
<br>(n = 131)
<br>Outcome
<br></span><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">C difficile</span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">–Related Complication or Death Within 30 d, No. (%)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Complication</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">b
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">10 (7.6)
<br>Death</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">c
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">11 (8.4)
<br>Complication or death
<br>18 (13.7)
<br></span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Repeat </span><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">C difficile </span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Testing Within 14 d, No. (%)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Retested
<br>Positive toxin test result
<br></span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Repeat </span><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">C difficile </span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Testing at 15-30 d, No. (%)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Tested
<br>Positive toxin test result
<br></span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Treatment Within 14 d
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Metronidazole or oral vancomycin, No. (%)</span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:3px">d
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Duration of metronidazole or oral
<br>vancomycin, if treated, median (IQR), d
<br>Non–</span><span style="font-family: GNJLEB+GuardianAgateSans1D-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">antibiotic, No. (%)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Duration of non–</span><span style="font-family: GNJLEB+GuardianAgateSans1D-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">antibiotic, if
<br>treated, median (IQR), d
<br></span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Treatment at 15-30 d
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">Metronidazole or oral vancomycin, No. (%)
<br>Duration of metronidazole or oral
<br>vancomycin, if treated, median (IQR), d
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Abbreviations: IQR, interquartile range; Tox+/PCR+, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin
<br>immunoassay positive and polymerase chain reaction positive; Tox−/PCR+, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C
<br>difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin immunoassay negative and polymerase chain reaction positive;
<br>Tox−/PCR−, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin immunoassay negative and polymerase chain
<br>reaction negative.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">a </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">value for significance across 3 groups.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">b </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Intensive care unit care, colectomy, or megacolon related to </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection. The Tox+/PCR+ complications included 3 fulminant colitis or
<br>megacolon and 7 intensive care unit care related to </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection. Two
<br>Tox−/PCR+ patients with partially treated complications diagnosed as having a
<br>positive toxin test result before day 1 were excluded. The Tox−/PCR−
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:203px; top:5346px; width:36px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">131 (100)
<br>14 (11-14)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:207px; top:5377px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">98 (74.8)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">11 (3-14)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:207px; top:5275px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">14 (10.7)
<br>3 (2.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:207px; top:5310px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">26 (19.8)
<br>14 (10.7)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:207px; top:5419px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">75 (57.3)
<br>9 (3-14)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:301px; top:5196px; width:31px; height:16px;"><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Tox−/PCR+
<br>(n = 162)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:309px; top:5227px; width:20px; height:32px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">0
<br>1 (0.6)
<br>1 (0.6)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:305px; top:5275px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">61 (37.7)
<br>13 (8.0)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:305px; top:5310px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">18 (11.1)
<br>5 (3.1)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:305px; top:5346px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">66 (40.7)
<br>6 (3-11)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:301px; top:5377px; width:32px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">141 (87.0)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">10 (4-14)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:305px; top:5419px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">35 (21.6)
<br>4 (3-15)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:398px; top:5185px; width:54px; height:26px;"><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">C difficile </span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Negative
<br>Tox−/PCR−
<br>(n = 1123)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:496px; top:5203px; width:23px; height:8px;"><span style="font-family: GNJLEA+GuardianAgateSans-MediumIt; font-size:6px">P </span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:6px">Value</span><span style="font-family: GNJLDP+GuardianAgateSansGR-Medium; font-size:3px">a
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:406px; top:5227px; width:20px; height:32px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">3 (0.3)
<br>0
<br>3 (0.3)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:398px; top:5275px; width:31px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">374 (33.3)
<br>17 (1.5)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:398px; top:5310px; width:28px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">106 (9.4)
<br>10 (0.9)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:398px; top:5346px; width:31px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">361 (32.1)
<br>5 (2-9)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:398px; top:5377px; width:32px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">912 (81.2)
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">10 (4-14)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:398px; top:5419px; width:31px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">137 (12.2)
<br>6 (3-9)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:496px; top:5227px; width:17px; height:32px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br>&lt;.001
<br>&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:496px; top:5275px; width:17px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br>&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:496px; top:5310px; width:17px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.001
<br>&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:496px; top:5346px; width:17px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br>&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:500px; top:5377px; width:9px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.03
<br></span><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">.13
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:496px; top:5419px; width:17px; height:20px;"><span style="font-family: GNJLCO+GuardianAgateSans1GR-Regular; font-size:6px">&lt;.001
<br>&lt;.001
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:306px; top:5449px; width:227px; height:94px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">complications included 3 intensive care unit care related to </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection</span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">.
<br>P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">&lt; .001 for Tox+/PCR+ vs Tox−/PCR+ and </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">&gt; .99 for Tox−/PCR+ vs
<br>Tox−/PCR−.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">c </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">All-cause mortality within 30 days was 14 (10.7%), 23 (14.2%), and 98 (8.7%),
<br>respectively, for the 3 groups. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">= .08 for all groups and </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">= .21 for Tox+/PCR+
<br>vs Tox−/PCR+. For </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection–related death, </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">&lt; .001 for Tox+/PCR+ vs
<br>Tox−/PCR+ and </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">P </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">= .13 Tox−/PCR+ vs Tox−/PCR−.
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:4px">d </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Full treatment (</span><span style="font-family: GNJLJA+MathematicalPi-One; font-size:4px">ⱖ</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">10 days) and partial treatment (1-9 days) values were 119
<br>(90.8%) and 12 (9.2%), respectively; 21 (13.0%) and 45 (27.8%), respectively;
<br>and 82 (7.3%) and 279 (24.8%), respectively, for the 3 groups.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:5575px; width:227px; height:252px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Tox−/PCR+ patients retested positive by the clinical toxin
<br>immunoassay in a subsequent sample. However, the relative
<br>lack of adverse events in this subgroup suggests that these
<br>patients are also at lower risk of complications than clinical
<br>toxin immunoassay–positive patients and routine treatment
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">is unnecessary.
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">These results are consistent w ith a large retrospective
<br>study</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">36 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">that found no </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">–related complications and
<br>lower mortality among hospitalized patients with negative
<br>toxin results. Our findings also agree w ith several smaller
<br>studies</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">11,14,37-41 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">and one large, multicenter study</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">21 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">that re-
<br>ported milder symptoms or a lower mortality rate in toxin-
<br>negative patients with positive PCR results. Other studies</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">42-45
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">that have investigated clinical characteristics of Tox−/PCR+ pa-
<br>tients were generally underpowered or not designed to com-
<br>pare outcomes. Finally, there are reports of patients with se-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">vere or complicated CDI missed by toxin tests,</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">43,46 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">but our data
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">suggest that such patients are rare.
<br>Strengths of our study include the prospective study de-
<br>sign, large sample size, nonreporting of PCR results, measure-
<br>ment of duration of diarrhea, inclusion of patients without </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">for comparison, and rigorous evaluation of </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">–
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:306px; top:5575px; width:227px; height:252px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">related complications and deaths. We quantified fecal </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diffi-
<br>cile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">DNA, toxins, and inflammation to provide mechanistic in-
<br>s ight into the rea son s fo r the d i f fe rent te s t re su l t s and
<br>outcomes. The primary weakness of the study was the inabil-
<br>ity to achieve equivalent risk allocation between groups. In ad-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">dition, we cannot exclude the possibility that empirical treat-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">ment affected outcomes in some Tox−/PCR+ patients, but the
<br>outcome differences we observed remained when these pa-
<br>tients were removed. It is also possible that our outcome ad-
<br>judicators were influenced by positive toxin results, but 26 of
<br>42 Tox+/PCR+ patients with ICU care or death (61.9%) were
<br>judged not to have a CDI-related outcome, indicating that the
<br>adjudication was a highly discriminatory process overall. Fi-
<br>nally, we cannot exclude the possibility that systematic un-
<br>derrecording of stools in patients with negative toxin results
<br>could account for the shorter duration of diarrhea in these pa-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tients. However, our requirement of 2 or more days without
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">diarrhea to end an episode would make it unlikely that under-
<br>recording by individual nurses would have a significant ef-
<br>fect on our diarrhea measure.
<br>Molecular tests have the potential benefits of decreasing
<br>the need for repeat testing and empirical treatment because
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:40px; top:5842px; width:14px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1798
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:5842px; width:195px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:268px; top:5842px; width:35px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:458px; top:5842px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:5860px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:67px; top:5168px; width:466px; height:13px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5182px; width:133px; height:31px;"></span>
<span style="position:absolute; border: black 1px solid; left:200px; top:5182px; width:292px; height:13px;"></span>
<span style="position:absolute; border: black 1px solid; left:493px; top:5182px; width:41px; height:31px;"></span>
<span style="position:absolute; border: black 1px solid; left:200px; top:5196px; width:292px; height:18px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5114px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5167px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5182px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:203px; top:5196px; width:189px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:398px; top:5196px; width:91px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5214px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5226px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5238px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5250px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5262px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5274px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5286px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5298px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5310px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5322px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5334px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5346px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5358px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5376px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5388px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5406px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5418px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5430px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5448px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5448px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:67px; top:5560px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:5884px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:5884px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:5944px; width:612px; height:792px;"></span>
<div style="position:absolute; top:5944px;"><a name="8">Page 8</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:5974px; width:130px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:448px; top:5974px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Original Investigation Research
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:6004px; width:227px; height:287px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">of their high negative predictive value and may have a role
<br>in infection prevention if Tox−/PCR+ patients contribute to
<br>the spread of </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">in health care facilities.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">34,43,47 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">How-
<br>ever, our results offer compelling evidence that as many as
<br>half of the patients with positive </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">PCR test results
<br>are likely to be overdiagnosed and exposed to unnecessary
<br>treatment at institutions using molecular tests. The number
<br>of pat ients potent ia l ly affec ted by th is issue is mass ive .
<br>Most inst itut ions exper ience a 50% to 100% inc rease in
<br>reported CDI after switching to molecular tests, and the pro-
<br>portion of institutions using molecular </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff icile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tests has
<br>increased dramatically since initiation in 2009 of the first
<br>FDA-approved molecular test.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">11-15 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">In 2014, almost 44% of
<br>NHSN acute care facilities reported using molecular tests for
<br>CDI diagnosis (NHSN, written communication, September
<br>15, 2014).
<br>Therefore, there is an urgent need to educate physicians
<br>that molecular tests are not specific for CDI, even in the pres-
<br>ence of symptoms, and patients with positive PCR results do
<br>not necessarily need treatment. Similarly, while underdiag-
<br>nosis may occur with lack of testing,</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">48 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">policy makers should
<br>be aware that molecular </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tests are a major cause of
<br>overdiagnosis and consider the potential costs of overtreat-
<br>ment in recommendations and analyses. Laboratories need to
<br>be aware that rejection of formed stool samples is not suffi-
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:6004px; width:227px; height:183px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">cient to ensure that all positive molecular </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">results rep-
<br>resent disease.
<br>We concur with authors in the United Kingdom that mo-
<br>lecular tests should not be used as a stand-alone diagnostic test
<br>for CDI and diagnostic recommendations should move back in
<br>the direction of defining clinical disease as a positive toxin re-
<br>sult in patients with diarrhea.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">21,49 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Most toxin-negative pa-
<br>tients with </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">do not need specific treatment, although
<br>th e re m ay b e a ro l e fo r id en t i f y ing c a r r i e r s to p reven t
<br>transmission.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">21,43 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Future studies should focus on developing di-
<br>agnostic approaches to accurately distinguish patients with ac-
<br>tive infection vs colonization, which may include quantitation
<br>of </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">DNA, toxins, or host response. In the meantime,
<br>2-step testing with a screening test, such as PCR or glutamate
<br>dehydrogenase antigen detection, followed by a toxin test to
<br>confirm active infection is a reasonable diagnostic strategy.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">21,49
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:6215px; width:227px; height:76px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:9px">Conclusions
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Up to half of the patients with positive molecular test results for
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">do not experience adverse events without treatment
<br>and do not need treatment for CDI. Exclusive reliance on mo-
<br>lecular tests for </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">diagnosis is likely to result in overdi-
<br>agnosis, unnecessary treatment, and increased health care costs.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:6313px; width:147px; height:341px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">ARTICLE INFORMATION
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Accepted for Publication: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">May 26, 2015.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Published Online: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">September 8, 2015.
<br>doi:10.1001/jamainternmed.2015.4114.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Author Affiliations: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Department of Pathology and
<br>Laboratory Medicine, University of California Davis
<br>School of Medicine, Sacramento (Polage, Gyorke,
<br>Kennedy, Leslie, Wang); Division of Infectious
<br>Diseases, Department of Internal Medicine,
<br>University of California Davis School of Medicine,
<br>Sacramento (Polage, Nguyen, Lee, Solnick, Cohen);
<br>Department of Microbiology and Immunology,
<br>University of Michigan Medical School, Ann Arbor
<br>(Leslie); Center for Healthcare Policy and Research,
<br>University of California Davis, Sacramento (Chin,
<br>Romano); Yolo County Health Department,
<br>Woodland, California (Wang); Department of
<br>Laboratory Medicine, Memorial Sloan Kettering
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Cancer Center, New York, New York (Huang, Tang);
<br>Department of Clinical Laboratory, First Affiliated
<br>Hospital of Sun Yat-sen University, Guangzhou,
<br>Guangdong, China (Huang); Weill Medical College
<br>of Cornell University, New York, New York (Tang);
<br>Division of Biostatistics, Department of Public
<br>Health Sciences, University of California Davis
<br>School of Medicine, Sacramento (Kim, Taylor);
<br>Division of General Medicine, Department of
<br>Internal Medicine, University of California Davis
<br>School of Medicine, Sacramento (Romano); Division
<br>of General Pediatrics, Department of Pediatrics,
<br>University of California Davis School of Medicine,
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Sacramento (Romano); Department of Emergency
<br>Medicine, University of California Davis School of
<br>Medicine, Sacramento (Panacek, Goodell);
<br>Department of Medical Microbiology and
<br>Immunology, University of California Davis School
<br>of Medicine, Sacramento (Solnick).
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:236px; top:6313px; width:145px; height:344px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Author Contributions</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">: Dr Polage had full access to
<br>all the data in the study and takes responsibility for
<br>the integrity of the data and the accuracy of the
<br>analysis.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Study concept and design: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Polage, Chin, Romano,
<br>Cohen.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Acquisition, analysis, or interpretation of data:
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Polage, Gyorke, Kennedy, Leslie, Chin, Wang,
<br>Nguyen, Huang, Tang, Lee, Panacek, Goodell,
<br>Solnick, Cohen.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Drafting of the manuscript: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Polage.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Critical revision of the manuscript for important
<br>intellectual content: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">All authors.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Statistical analysis: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Polage, Kim, Taylor.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Obtained funding: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Polage, Romano.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Administrative, technical, or material support:
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Polage, Panacek.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Study supervision: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Polage.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Conflict of Interest Disclosures: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">All authors have
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">completed and submitted the ICMJE Form for
<br>Disclosure of Potential Conflicts of Interest. Dr
<br>Polage reported receiving research materials (ie,
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">diagnostic test kits and
<br>reagents) from Meridian Biosciences, Cepheid,
<br>TechLab, and Alere; and honoraria for a webinar
<br>about diagnostic testing for </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">and
<br>nosocomial diarrhea from Alere. Dr Nguyen
<br>reported receiving research funding for
<br>pharmaceutical clinical trials of treatment for
<br>patients with </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">from Merck, Cubist, and
<br>Viropharma. Dr Tang reported receiving research
<br>funding and materials from ACEA Biosciences. Dr
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Cohen reported serving on an advisory board for
<br>Merck and receiving research funding for
<br>pharmaceutical clinical trials of treatment for
<br>patients with </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">from Merck, Viropharma,
<br>Seres Health, and Actelion. No other disclosures
<br>were reported.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:395px; top:6313px; width:147px; height:356px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Funding/Support: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">This study was supported by
<br>grants UL1 RR024146 and TL1 RR024145-06 from
<br>the National Center for Research Resources (Dr
<br>Polage), grant UL1TR000002 and linked award
<br>TL1TR000133 from the National Center for
<br>Advancing Translational Sciences (Dr Chin), and grant
<br>T32HS022236 from the Agency for Healthcare
<br>Research and Quality through the Quality Safety
<br>Comparative Effectiveness Research Training
<br>Program (Dr Chin). </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">diagnostic test
<br>kits and reagents were received from Meridian
<br>Biosciences, Cepheid, TechLab, and Alere.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Role of the Funder/Sponsor: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">The industry
<br>contributors to this study had no role in the design
<br>and conduct of the study; the collection,
<br>management, analysis, and interpretation of the
<br>data; or the preparation, review, or approval of the
<br>manuscript.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">Additional Contributions: </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">We thank the following
<br>for their contributions without compensation: staff
<br>of the University of California Davis Medical Center
<br>Clinical Microbiology Laboratory for assistance with
<br>testing and processing samples; Jennifer Brown,
<br>MD (University of California Davis School of
<br>Medicine) for blinded electronic health record
<br>reviews; and all the volunteers who participated as
<br>undergraduates at the University of California Davis
<br>or California State University, Sacramento, in
<br>patient enrollment, clinical data collection, or
<br>sample processing, including Sameer Aggarwal, BS,
<br>Robert Araiza, BS, Adeel Ashfaq, BS, Mercy
<br>Bechtold, BS, Joel Breck, BA, MPH, Jenna DeYoung,
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">BS, Tu Dinh, BS, Timothy Fong, BS, MPH, Kaitlin
<br>Gee, BS, Megan Gilbert, BS, Breana Hill, BS, Chae Ji
<br>Kim, BS, Bryan Lee, BS, Dan O’Brien, BS, Thomas
<br>Osterberg-Diess, BS, Erik Pennell, BS, Roberto
<br>Ramos, BS, Daniel Sadoma, BS, Natalie Telis, BS,
<br>Joanna Tripet-Diel, BS, MPH, Andrew Tubbs, BS,
<br>William Valcheck, BS, and Alvin Au Yeung, BS.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:6684px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:6684px; width:236px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted) JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:555px; top:6684px; width:14px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1799
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:6702px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:76px; top:5956px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:6210px; width:53px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:315px; top:6212px; width:227px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:6304px; width:466px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:6726px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:6726px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:6786px; width:612px; height:792px;"></span>
<div style="position:absolute; top:6786px;"><a name="9">Page 9</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:6816px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Research Original Investigation
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:404px; top:6816px; width:130px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:6848px; width:147px; height:646px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">REFERENCES
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Magill SS, Edwards JR, Bamberg W, et al;
<br>Emerging Infections Program Healthcare-
<br>Associated Infections and Antimicrobial Use
<br>Prevalence Survey Team. Multistate
<br>point-prevalence survey of health care–associated
<br>infections. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">N Engl J Med</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2014;370(13):1198-1208.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">2</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Lucado J, Gould C, Elixhauser A. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br>difficile Infections (CDI) in Hospital Stays, 2009:
<br>Statistical Brief #124</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Rockville, MD: Agency for Health
<br>Care Policy and Research; 2006-2012. Healthcare
<br>Cost and Utilization Project (HCUP) Statistical Briefs.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">3</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Rupnik M, Wilcox MH, Gerding DN. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br>difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection: new developments in epidemiology
<br>and pathogenesis. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Nat Rev Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2009;7(7):526-
<br>536.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">4</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. McDonald LC, Lessa F, Sievert D, et al; Centers
<br>for Disease Control and Prevention (CDC). Vital
<br>signs: preventing </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infections.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">MMWR Morb Mortal Wkly Rep</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2012;61(9):157-162.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">5</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Zilberberg MD, Shorr AF, Kollef MH. Increase in
<br>adult </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">–related hospitalizations
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">and case-fatality rate, United States, 2000-2005.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Emerg Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2008;14(6):929-931.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">6</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Kang J, Sickbert-Bennett EE, Brown VM, Weber
<br>DJ, Rutala WA. Changes in the incidence of health
<br>care–associated pathogens at a university hospital
<br>from 2005 to 2011. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Am J Infect Control</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2014;42(7):
<br>770-775.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">7</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Dubberke ER, Olsen MA. Burden of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br>difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">on the healthcare system. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">.
<br>2012;55(suppl 2):S88-S92.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">8</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. McDonald LC, Killgore GE, Thompson A, et al. An
<br>epidemic, toxin gene–variant strain of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br>difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">N Engl J Med</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2005;353(23):2433-2441.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">9</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Pépin J, Valiquette L, Alary ME, et al. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br>difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">–associated diarrhea in a region of Quebec
<br>from 1991 to 2003: a changing pattern of disease
<br>severity. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">CMAJ</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2004;171(5):466-472.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">10</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Burnham CA, Carroll KC. Diagnosis of
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection: an ongoing
<br>conundrum for clinicians and for clinical
<br>laboratories. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Microbiol Rev</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2013;26(3):604-630.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">11</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Longtin Y, Trottier S, Brochu G, et al. Impact of
<br>the type of diagnostic assay on </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection and complication rates in a mandatory
<br>reporting program. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2013;56(1):67-73.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">12</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Moehring RW, Lofgren ET, Anderson DJ. Impact
<br>of change to molecular testing for </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection on healthcare facility–associated
<br>incidence rates. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Infect Control Hosp Epidemiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">.
<br>2013;34(10):1055-1061.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">13</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Fong KS, Fatica C, Hall G, et al. Impact of PCR
<br>testing for </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">on incident rates and
<br>potential on public reporting: is the playing field
<br>level? </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Infect Control Hosp Epidemiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2011;32(9):
<br>932-933.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">14</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Koo HL, Van JN, Zhao M, et al. Real-time
<br>polymerase chain reaction detection of
<br>asymptomatic </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">colonization and
<br>rising </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C. difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">–associated disease rates. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Infect
<br>Control Hosp Epidemiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2014;35(6):667-673.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">15</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Gould CV, Edwards JR, Cohen J, et al;
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection Surveillance
<br>Investigators, Centers for Disease Control and
<br>Prevention. Effect of nucleic acid amplification
<br>testing on population-based incidence rates of
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:227px; top:6848px; width:147px; height:649px;"><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2013;57
<br>(9):1304-1307.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">16</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Bartlett JG, Taylor NS, Chang T, Dzink J. Clinical
<br>and laboratory observations in </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">colitis. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Am J Clin Nutr</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 1980;33(11)(suppl):2521-2526.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">17</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Gerding DN, Johnson S, Peterson LR, Mulligan
<br>ME, Silva J Jr. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">–associated
<br>diarrhea and colitis. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Infect Control Hosp Epidemiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">.
<br>1995;16(8):459-477.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">18</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Bartlett JG, Gerding DN. Clinical recognition
<br>and diagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin
<br>Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2008;46(suppl 1):S12-S18.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">19</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Wilcox MH, Planche T, Fang FC, Gilligan P. What
<br>is the current role of algorithmic approaches for
<br>diagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection? </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin
<br>Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2010;48(12):4347-4353.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">20</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Dubberke ER, Han Z, Bobo L, et al. Impact of
<br>clinical symptoms on interpretation of diagnostic
<br>assays for </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infections. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin
<br>Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2011;49(8):2887-2893.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">21</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Planche TD, Davies KA, Coen PG, et al.
<br>Differences in outcome according to </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">testing method: a prospective multicentre
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">diagnostic validation study of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Lancet Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2013;13(11):936-945.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">22</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Kyne L, Warny M, Qamar A, Kelly CP.
<br>Asymptomatic carriage of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">and
<br>serum levels of IgG antibody against toxin A. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">N Engl
<br>J Med</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2000;342(6):390-397.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">23</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Samore MH, DeGirolami PC, Tlucko A,
<br>Lichtenberg DA, Melvin ZA, Karchmer AW.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">colonization and diarrhea at a
<br>tertiary care hospital. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 1994;18(2):181-
<br>187.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">24</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Leekha S, Aronhalt KC, Sloan LM, Patel R,
<br>Orenstein R. Asymptomatic </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">colonization in a tertiary care hospital: admission
<br>prevalence and risk factors. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Am J Infect Control</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">.
<br>2013;41(5):390-393.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">25</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Alasmari F, Seiler SM, Hink T, Burnham CA,
<br>Dubberke ER. Prevalence and risk factors for
<br>asymptomatic </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">carriage. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin
<br>Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2014;59(2):216-222.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">26</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Polage CR, Solnick JV, Cohen SH. Nosocomial
<br>diarrhea: evaluation and treatment of causes other
<br>than </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2012;55(7):
<br>982-989.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">27</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Brecher SM, Novak-Weekley SM, Nagy E.
<br>Laboratory diagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infections: there is light at the end of the colon. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin
<br>Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2013;57(8):1175-1181.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">28</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Ryder AB, Huang Y, Li H, et al. Assessment of
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infections by quantitative
<br>detection of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">tcdB </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin by use of a real-time cell
<br>analysis system. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2010;48(11):4129-4134.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">29</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Leslie JL, Cohen SH, Solnick JV, Polage CR. Role
<br>of fecal </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">load in discrepancies
<br>between toxin tests and PCR: is quantitation the
<br>next step in </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">C. difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">testing? </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Eur J Clin Microbiol
<br>Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2012;31(12):3295-3299.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">30</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Huang B, Jin D, Zhang J, et al. Real-time cellular
<br>analysis coupled with a specimen enrichment
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">accurately detects and quantifies </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxins in stool. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2014;52(4):1105-1111.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">31</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Viscidi R, Laughon BE, Yolken R, et al. Serum
<br>antibody response to toxins A and B of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br>difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 1983;148(1):93-100.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:386px; top:6848px; width:147px; height:652px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">32</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Cardona DM, Rand KH. Evaluation of repeat
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">enzyme immunoassay testing.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2008;46(11):3686-3689.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">33</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Borek AP, Aird DZ, Carroll KC. Frequency of
<br>sample submission for optimal utilization of the cell
<br>culture cytotoxicity assay for detection of
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2005;43
<br>(6):2994-2995.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">34</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Khanna S, Pardi DS, Rosenblatt JE, Patel R,
<br>Kammer PP, Baddour LM. An evaluation of repeat
<br>stool testing for </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection by
<br>polymerase chain reaction. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin Gastroenterol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">.
<br>2012;46(10):846-849.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">35</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Deshpande A, Pasupuleti V, Patel P, et al.
<br>Repeat stool testing to diagnose Clostridium
<br>difficile infection using enzyme immunoassay does
<br>not increase diagnostic yield. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Gastroenterol
<br>Hepatol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2011;9(8):665-669.e1. doi:10.1016/j.cgh.2011
<br>.04.030.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">36</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Polage CR, Chin DL, Leslie JL, Tang J, Cohen
<br>SH, Solnick JV. Outcomes in patients tested for
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxins. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Diagn Microbiol Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">.
<br>2012;74(4):369-373.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">37</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Gerding DN, Olson MM, Peterson LR, et al.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">–associated diarrhea and colitis in
<br>adults: a prospective case-controlled epidemiologic
<br>study. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Arch Intern Med</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 1986;146(1):95-100.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">38</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Walker AS, Eyre DW, Wyllie DH, et al; Infections
<br>in Oxfordshire Research Database. Relationship
<br>between bacterial strain type, host biomarkers, and
<br>mortality in </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Infect
<br>Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2013;56(11):1589-1600.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">39</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. de Jong E, de Jong AS, Bartels CJ, van der
<br>Rijt-van den Biggelaar C, Melchers WJ, Sturm PD.
<br>Clinical and laboratory evaluation of a real-time PCR
<br>for </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin A and B genes. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Eur J
<br>Clin Microbiol Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2012;31(9):2219-2225.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">40</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Beaulieu C, Dionne LL, Julien AS, Longtin Y.
<br>Clinical characteristics and outcome of patients
<br>with Clostridium difficile infection diagnosed by
<br>PCR versus a three-step algorithm. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin Microbiol
<br>Infect</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2014;20(10):1067-1073.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">41</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Baker I, Leeming JP, Reynolds R, Ibrahim I,
<br>Darley E. Clinical relevance of a positive molecular
<br>test in the diagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Hosp Infect</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2013;84(4):311-315.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">42</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Kaltsas A, Simon M, Unruh LH, et al. Clinical
<br>and laboratory characteristics of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection in patients with discordant diagnostic test
<br>results. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2012;50(4):1303-1307.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">43</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Guerrero DM, Chou C, Jury LA, Nerandzic MM,
<br>Cadnum JC, Donskey CJ. Clinical and infection
<br>control implications of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection
<br>with negative enzyme immunoassay for toxin. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clin
<br>Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2011;53(3):287-290.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">44</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Humphries RM, Uslan DZ, Rubin Z.
<br>Performance of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">toxin enzyme
<br>immunoassay and nucleic acid amplification tests
<br>stratified by patient disease severity. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Clin Microbiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">.
<br>2013;51(3):869-873.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">45</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Berry N, Sewell B, Jafri S, et al. Real-time
<br>polymerase chain reaction correlates well with
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">clinical diagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">infection.
<br></span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">J Hosp Infect</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2014;87(2):109-114.
<br></span><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">46</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Lashner BA, Todorczuk J, Sahm DF, Hanauer
<br>SB. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">culture–positive
<br>toxin-negative diarrhea. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Am J Gastroenterol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 1986;
<br>81(10):940-943.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:40px; top:7526px; width:16px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1800
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:67px; top:7526px; width:195px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:268px; top:7526px; width:35px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted)
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:458px; top:7526px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:7544px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:67px; top:6798px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:7568px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:7568px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<span style="position:absolute; border: gray 1px solid; left:0px; top:7628px; width:612px; height:792px;"></span>
<div style="position:absolute; top:7628px;"><a name="10">Page 10</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:7658px; width:130px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Overdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:448px; top:7658px; width:94px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Original Investigation Research
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:7690px; width:147px; height:45px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">47</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Sydnor ER, Lenhart A, Trollinger B, et al.
<br>Antimicrobial prescribing practices in response to
<br>different </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">diagnostic
<br>methodologies. </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Infect Control Hosp Epidemiol</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2011;
<br>32(11):1133-1136.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:236px; top:7690px; width:145px; height:54px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">48</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Davies KA, Longshaw CM, Davis GL, et al.
<br>Underdiagnosis of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">across Europe:
<br>the European, Multicentre, Prospective, Biannual,
<br>Point-Prevalence Study of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium difficile
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Infection in Hospitalised Patients With Diarrhoea
<br>(EUCLID). </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Lancet Infect Dis</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. 2014;14(12):1208-1219.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:395px; top:7690px; width:147px; height:45px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">49</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. Department of Health, United Kingdom. Updated
<br>guidance on the diagnosis and reporting of </span><span style="font-family: GNJKJM+GuardianSans-RegularIt; font-size:6px">Clostridium
<br>difficile</span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">. https://www.gov.uk/government/publications
<br>/updated-guidance-on-the-diagnosis-and-reporting
<br>-of-clostridium-difficile. Accessed July 8, 2015.
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:7756px; width:310px; height:78px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:8px">Invited Commentary
<br></span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:16px">Diagnosis of </span><span style="font-family: GNJKIK+GuardianSans-MediumIt; font-size:16px">Clostridium difficile </span><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:16px">Infection
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:16px">Treat the Patient, Not the Test
<br></span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">Erik R. Dubberke, MD, MSPH; Carey-Ann D. Burnham, PhD
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:7971px; width:77px; height:9px;"><span style="font-family: GNJKIJ+GuardianSans-Medium; font-size:6px">Related article </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">page 1792
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:7848px; width:227px; height:505px;"><span style="font-family: GNJLMA+GuardianTextEgyp-Bold; font-size:8px">No laboratory test </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">can diagnose </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">Clostridium diff icile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">infec-
<br>tion (CDI). Rather, CDI is a clinical diagnosis that can be sup-
<br>ported by laboratory data . Wh i le a d iagnost ic assay may
<br>indicate the absence or presence of the organism or its tox-
<br>ins, the test by itself does not determine who does or does
<br>not have CDI.
<br>One of the challenges in diagnosing CDI is that there are
<br>more asymptomatic </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">carriers than there are people
<br>with CDI in the community and in the hospital. It is estimated
<br>3% to 7% of the healthy adult
<br>population are colonized with
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C d i ff i c i l e </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">. </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">1 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">A symp tomat ic
<br>colonization is more common among individuals with inpa-
<br>tient health care exposures. Between 4.4% and 15% of people
<br>are colonized with </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">on admission to the hospital, with
<br>as many as 50% of persons living in long-term care facilities
<br>colonized.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">1 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">To add to the dilemma, diarrhea is frequent among
<br>those with health care exposures. Although </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">is the
<br>most common health care–associated pathogen in the United
<br>States and CDI is a major cause of morbidity and mortality, it
<br>typically affects less than 1% of hospitalized patients and is the
<br>cause of diarrhea in only 5% to 10% of hospitalized people who
<br>have diarrhea and are tested for </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">1
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">In the absence of clinical data, it is impossible to deter-
<br>mine if a positive </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">diagnostic assay represents asymp-
<br>tomatic </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diff ic ile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">colonization or CDI. To date, few high-
<br>quality studies have determined the true performance of
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">diagnostic assays when the clinical picture is taken
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">into account. This dilemma is why knowledge of the clinical
<br>context of the patient is so important when evaluating </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C dif-
<br>ficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">assays, as illustrated by Polage et al</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">2 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">in this issue of </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">JAMA
<br>Internal Medicine</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">.
<br>Polage et al</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">2 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">demonstrate that patients who were </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C diffi-
<br>cile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">negative by toxin enzyme immunoassay (EIA) but posi-
<br>tive by polymerase chain reaction (PCR) (Tox−/PCR+) had sig-
<br>nificantly less severe diarrhea at the time of testing, more rapid
<br>resolution of diarrhea, and fewer CDI-related complications or
<br>deaths (</span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">P </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">&lt; .001 for all) compared with patients who were posi-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">tive by toxin EIA and PCR (Tox+/PCR+). The presentation and
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">outcomes of patients with specimens that were Tox−/PCR+
<br>were no different from those of patients with specimens that
<br>were negative by both toxin EIA and PCR. The strengths of this
<br>study are its large sample size, the inclusion of high-quality
<br>data about patients before and after the testing episode, the
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:315px; top:7849px; width:227px; height:505px;"><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">longitudinal follow-up of patients after discharge from the hos-
<br>pital, and the fact that the results of the PCR-based diagnos-
<br>tic assay were not reported to clinicians and so could not in-
<br>fluence their treatment decisions.
<br>The findings by Polage et al</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">2 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">are consistent with what is
<br>known about CDI, toxin EIAs, and PCR-based diagnostics for
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">. Fecal samples positive for toxin have higher bacte-
<br>rial and toxin levels in stool and higher levels of inflamma-
<br>tory markers than stool samples positive by PCR alone, indi-
<br>cating that those positive by PCR alone are more likely to have
<br>asymptomatic </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">carriage than CDI. The largest </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C dif-
<br>ficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">diagnostic comparison to date reported test results from
<br>6522 inpatient episodes and found that people positive for toxin
<br>were more likely to die compared with people colonized with
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">but without detectable toxin in stool.</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">3 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">Planche et al</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">3
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">also observed that mortality among individuals who were colo-
<br>nized with </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">but without detectable toxin was no dif-
<br>ferent from that among individuals who were not colonized
<br>with </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">.
<br>Another important observation by Polage et al,</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">2 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">which is
<br>consistent with prior literature, is that more of their patients
<br>were Tox−/PCR+ than Tox+/PCR+. The real-world perfor-
<br>mance of PCR when clinical data were taken into account in
<br>this study yielded a sensitivity of 100% and a specificity of
<br>87.4%, for a positive predictive value of 44.7%. In a much
<br>smaller study</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">4 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">in which our group prospectively interviewed
<br>and examined all patients who had stool samples included in
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">a </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">assay comparison, it was found that the specific-
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">ity of PCR-based diagnostics ranged from 84.3% to 86.1% when
<br>the clinical presentation of patients was considered, with a cor-
<br>responding positive predictive value of 44.0% to 47.1%. With
<br>such low positive predictive values, it is not surprising that
<br>there are numerous false positives with PCR testing. Indeed,
<br>the Centers for Disease Control and Prevention</span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:5px">5 </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">found that the
<br>CDI incidence increased by 43% to 67% at hospitals that change
<br>from toxin EIAs to PCR-based assays for detection.
<br>The increase in </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">C difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">detection associated with PCR-
<br>based diagnostics has serious implications at the hospital and
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">patient levels. More positive assays result in more patients in
<br></span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">contact precautions. Such precautions are costly in that they
<br>require resources such as single rooms and gowning. </span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">Clos-
<br></span><span style="font-family: GNJKNM+GuardianTextEgyp-RegularIt; font-size:8px">tridium difficile </span><span style="font-family: GNJKNN+GuardianTextEgypGR-Regular; font-size:8px">infection incidence data are available to the
<br>public (http://www.hospitalcompare.hhs.gov/), and these data
<br>may be used for value-based purchasing decisions (http://www
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:76px; top:8368px; width:76px; height:8px;"><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">jamainternalmedicine.com
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:307px; top:8368px; width:236px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">(Reprinted) JAMA Internal Medicine </span><span style="font-family: GNJKIL+GuardianSansGR-Regular; font-size:6px">November 2015 Volume 175, Number 11
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:556px; top:8368px; width:13px; height:9px;"><span style="font-family: GNJKJL+GuardianSans-Semibold; font-size:6px">1801
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:190px; top:8386px; width:220px; height:9px;"><span style="font-family: Arial-BoldMT; font-size:6px">Copyright 2015 American Medical Association. All rights reserved.
<br>Copyright 2015 American Medical Association. All rights reserved.
<br></span></div><span style="position:absolute; border: black 1px solid; left:76px; top:7640px; width:466px; height:14px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:7764px; width:186px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:356px; top:7764px; width:186px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:76px; top:7960px; width:9px; height:9px;"></span>
<span style="position:absolute; border: black 1px solid; left:78px; top:7965px; width:7px; height:0px;"></span>
<span style="position:absolute; border: black 1px solid; left:78px; top:7962px; width:2px; height:5px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:8410px; width:0px; height:8px;"></span>
<span style="position:absolute; border: black 1px solid; left:10px; top:8410px; width:378px; height:8px;"></span>
Downloaded From: http://archinte.jamanetwork.com/ by a University of California - Davis User  on 03/21/2016<div style="position:absolute; top:0px;">Page: <a href="#1">1</a>, <a href="#2">2</a>, <a href="#3">3</a>, <a href="#4">4</a>, <a href="#5">5</a>, <a href="#6">6</a>, <a href="#7">7</a>, <a href="#8">8</a>, <a href="#9">9</a>, <a href="#10">10</a></div>
</body></html>
